血液学および血栓塞栓性疾患ジャーナル
オープンアクセス

概要

Management of Bleeding Complications of Dabigatran

Jorge Labrador, Franciso S Lozano and José-Ramón González-Porras

Dabigatran etexilate is a new oral non-peptidic direct thrombin inhibitor approved by the FDA and EMA for stroke prevention in patients with non-valvular atrial fibrillation. Unlike warfarin, there are no antidotes available for reversing its anticoagulant effect, a strategy for the optimal management of major bleeding has not yet been developed, and most recommendations are based on expert opinions and small trials. This review aims to summarize the published data and identify potential issues in the management of bleeding complications associated with this drug.